App-Quantinova.ai

Apostream to isolate circulating tumor cells (CTC) from castration-resistant prostate cancer patients (CRPC) that express androgen receptor variant 7 (AR-V7) associated with resistance to AR-targeting drugs.

Darren W. Davis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Androgen Tear

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).

Ricardo Lima Barros Costa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Development of an automated and sensitive microfluidic device for circulating tumor cell (CTC) analysis and single cell capturing.

Priya Gogoi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Patterns of PD-L1 expression on circulating tumor cells in Japanese patients with advanced lung cancer.

Yasuhiro Koh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

EGFR mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.

Silvia Calabuig-Farinas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Association of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) with E-cadherin (E-CAD) expression and improved survival in breast cancer (BC).

Sofia Agelaki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Sensitive detection of CTCs in thoracic malignant tumors with a universal CTC-chip.

Kazue Yoneda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

Targeted next generation sequencing (NGS) of matched primary tumor, metastasis, circulating tumor cells (CTCs), and cell-free DNA (cfDNA) in a patient with advanced prostate cancer (PC).

Cory Michael Hugen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Circulating tumor microemboli as a prognostic factor for locally advanced or metastatic solid tumors.

Marcelo Corassa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The performance of a comprehensive CTC anti-body capture cocktail in the detection and phenotypic analysis of CTCs.

Veena M. Singh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

MD 1003

The largest sample size (2,200 cases) pooled analysis of LT-PCR achieving quantitative determination of folate receptor-positive CTCs for lung cancer in China.

Caicun Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Molecular detection of ROS1-rearranged circulating tumor cells (CTC) in non-small cell lung cancer (NSCLC) patients.

Man Chun Leong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Differential epithelial and mesenchymal CTC profiling according to non-small cell lung cancer (NSCLC) molecular subtype.

Colin R. Lindsay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Possibility of detection of circulating tumor cells (CTCs) in blood of patients with lung cancer.

Inna Arnoldovna Novikova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Studying the gene expression profile among circulating tumor cells.

Ioannis Papasotiriou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Single cell copy number variation analysis of circulating tumor cells in gastrointestinal cancer patients for study of intra-patient genomic heterogeneity.

Man Chun Leong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Association of Ki-67 expression in CTCs with disease relapse in patients with early breast cancer (BC) and affect by the administration of adjuvant chemotherapy.

Dimitrios Mavroudis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.

Steven J. Chmura - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A Phase 1 study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with advanced solid tumors.

Rebecca Sophie Kristeleit - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

BAL-101553

A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) after radical resection of metastases: RESORT trial.

Giuseppe Procopio - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Sorafenib

Filters

1671 Abstracts